We used a computer-generated sequence to randomly allocate patients ( 1:1 ; stratified by baseline inhaled corticosteroid use , with the balance of treatments maintained at country level ) to receive either indacaterol ( 150 g ) or tiotropium ( 18 g ) once-daily for 52 weeks .